You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 17, 2025

CLINICAL TRIALS PROFILE FOR PROCTOFOAM HC


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for PROCTOFOAM HC

Trial IDTitleStatusSponsorPhaseStart DateSummary
NCT00405288 ↗ The Safety of Proctofoam-HC in the Third Trimester of Pregnancy Completed Duchesnay Inc. 2006-11-01 The purpose of this study is to evaluate the fetal safety of topical application of Proctofoam-HC®, an antihemorrhoidal, in the third trimester of pregnancy.
NCT00405288 ↗ The Safety of Proctofoam-HC in the Third Trimester of Pregnancy Completed The Hospital for Sick Children 2006-11-01 The purpose of this study is to evaluate the fetal safety of topical application of Proctofoam-HC®, an antihemorrhoidal, in the third trimester of pregnancy.
>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 2 of 2 entries

Clinical Trial Conditions for PROCTOFOAM HC

Condition Name

110-0.100.10.20.30.40.50.60.70.80.911.1HemorrhoidsPregnancy[disabled in preview]
Condition Name for PROCTOFOAM HC
Intervention Trials
Hemorrhoids 1
Pregnancy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

10-0.100.10.20.30.40.50.60.70.80.911.1Hemorrhoids[disabled in preview]
Condition MeSH for PROCTOFOAM HC
Intervention Trials
Hemorrhoids 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for PROCTOFOAM HC

Trials by Country

+
Trials by Country for PROCTOFOAM HC
Location Trials
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for PROCTOFOAM HC

Clinical Trial Phase

0[disabled in preview]
Clinical Trial Phase for PROCTOFOAM HC
Clinical Trial Phase Trials
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

100.0%0-0.100.10.20.30.40.50.60.70.80.911.1Completed[disabled in preview]
Clinical Trial Status for PROCTOFOAM HC
Clinical Trial Phase Trials
Completed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for PROCTOFOAM HC

Sponsor Name

trials000001111111Duchesnay Inc.The Hospital for Sick Children[disabled in preview]
Sponsor Name for PROCTOFOAM HC
Sponsor Trials
Duchesnay Inc. 1
The Hospital for Sick Children 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

50.0%50.0%0-0.100.10.20.30.40.50.60.70.80.911.1IndustryOther[disabled in preview]
Sponsor Type for PROCTOFOAM HC
Sponsor Trials
Industry 1
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

PROCTOFOAM HC: Clinical Trials Update, Market Analysis, and Future Projections

PROCTOFOAM HC, a combination of hydrocortisone acetate and pramoxine hydrochloride, has been a staple in the treatment of hemorrhoids and other anorectal conditions for decades. This article delves into the latest clinical trials, market analysis, and future projections for this widely used medication.

The Evolution of PROCTOFOAM HC

PROCTOFOAM HC has been on the Canadian market for over 25 years, combining the anti-inflammatory action of hydrocortisone with the surface anesthetic effect of pramoxine HCl[7]. Its long-standing presence in the market speaks volumes about its efficacy and safety profile.

Composition and Mechanism of Action

PROCTOFOAM HC is a topical aerosol foam containing 1% hydrocortisone acetate and 1% pramoxine hydrochloride[5]. This unique combination provides both anti-inflammatory and anesthetic properties, making it effective in treating various anorectal conditions.

Approved Indications

The medication is approved for temporary relief of anorectal inflammation, pruritus, pain, and swelling associated with:

  • Hemorrhoids
  • Proctitis
  • Cryptitis
  • Fissures
  • Pruritus ani
  • Postoperative pain[8]

Recent Clinical Trials: Efficacy and Safety

Recent clinical trials have shed new light on the efficacy and safety of PROCTOFOAM HC, particularly in specific patient populations.

Effectiveness in Pregnancy

A prospective, open-label, observational study evaluated the effectiveness of PROCTOFOAM HC in pregnant women during their last trimester.

The study concluded that PROCTOFOAM HC appears to provide effective treatment of hemorrhoids in late pregnancy[1].

This finding is particularly significant as it addresses a previously unmet need in obstetric care.

Fetal Safety Study

Another multicenter study assessed the fetal safety of third-trimester exposure to PROCTOFOAM HC.

The study found that when compared to controls, exposure to PROCTOFOAM HC was not associated with any adverse fetal effects on birth weight, gestational age, rates of prematurity, or pre- or postnatal complications[4].

This research provides crucial evidence supporting the safety of PROCTOFOAM HC use during pregnancy, a period when many medications are contraindicated.

Market Analysis: Current Position and Trends

The market for PROCTOFOAM HC has seen some fluctuations in recent years, influenced by various factors including supply chain disruptions and changing market dynamics.

Supply Chain Challenges

In 2022, PROCTOFOAM HC faced a shortage due to disruption in the manufacturing process. The estimated end date for this shortage was projected to be July 1, 2025[2]. However, it's worth noting that such projections can change based on various factors.

Market Reentry

Despite these challenges, PROCTOFOAM HC has shown resilience. In August 2020, Duchesnay Inc. announced that PROCTOFOAM HC was back on the Canadian market after resolving a temporary drug shortage[3]. This quick resolution demonstrates the product's importance in the market and the manufacturer's commitment to ensuring its availability.

Market Coverage

PROCTOFOAM HC is covered by most private insurers and by public insurance plans in several Canadian provinces and territories, including British Columbia, Alberta, New Brunswick, Nova Scotia, Newfoundland/Labrador, and the Yukon[3]. This wide coverage indicates strong market acceptance and demand for the product.

Competitive Landscape

While PROCTOFOAM HC has been a long-standing player in the hemorrhoid treatment market, it's important to consider the competitive landscape.

Unique Selling Proposition

PROCTOFOAM HC's combination of hydrocortisone and pramoxine gives it a unique position in the market. The hydrocortisone provides anti-inflammatory effects, while pramoxine offers local anesthetic properties, making it a comprehensive solution for anorectal discomfort.

Competitors

Other products in this space include:

  • Over-the-counter creams and ointments
  • Prescription-strength corticosteroid creams
  • Suppositories
  • Oral medications for more severe cases

However, PROCTOFOAM HC's foam formulation and combination of active ingredients set it apart from many competitors.

Future Projections and Market Opportunities

Looking ahead, several factors are likely to influence the future of PROCTOFOAM HC in the market.

Aging Population

With an aging global population, the incidence of hemorrhoids and other anorectal conditions is likely to increase. This demographic shift could drive increased demand for effective treatments like PROCTOFOAM HC.

Pregnancy-Safe Medications

The recent studies confirming PROCTOFOAM HC's safety and efficacy in pregnancy open up a significant market opportunity. As the first topical anti-hemorrhoidal agent studied for effectiveness in pregnancy[1], PROCTOFOAM HC could become the go-to treatment for pregnant women suffering from hemorrhoids.

Potential for New Indications

While currently approved for several anorectal conditions, there may be potential for PROCTOFOAM HC to be studied for additional indications. This could expand its market reach and solidify its position in the gastrointestinal treatment landscape.

Challenges and Considerations

Despite its strong position, PROCTOFOAM HC faces several challenges that could impact its future market performance.

Manufacturing Stability

The recent supply chain disruptions highlight the need for robust manufacturing processes. Ensuring a stable supply will be crucial for maintaining market share and physician confidence.

Generic Competition

As an older product, PROCTOFOAM HC may face increased competition from generic alternatives in the future. Maintaining its unique formulation and emphasizing its proven efficacy will be key to retaining market share.

Regulatory Environment

Changes in regulatory requirements, particularly around topical corticosteroids, could impact PROCTOFOAM HC's market position. Staying ahead of regulatory trends and maintaining a strong safety profile will be important.

Innovation and Research Opportunities

To maintain and grow its market position, ongoing innovation and research will be crucial for PROCTOFOAM HC.

Formulation Improvements

There may be opportunities to improve the formulation, perhaps by enhancing its absorption or extending its duration of action. Such improvements could further differentiate PROCTOFOAM HC from competitors.

Expanded Clinical Studies

While recent studies have focused on pregnancy, there may be other patient populations or conditions where PROCTOFOAM HC could prove beneficial. Conducting studies in these areas could open up new markets.

Combination Therapies

Exploring the potential of combining PROCTOFOAM HC with other treatments could lead to more comprehensive treatment regimens for anorectal conditions.

Market Expansion Strategies

Several strategies could be employed to expand PROCTOFOAM HC's market presence.

Geographic Expansion

While well-established in Canada, there may be opportunities to expand into new geographic markets, particularly in regions with aging populations or high incidence of anorectal conditions.

Patient Education

Increasing patient awareness about the benefits of PROCTOFOAM HC, particularly its unique foam formulation and combination of active ingredients, could drive increased demand.

Healthcare Provider Outreach

Engaging with healthcare providers, particularly obstetricians and gastroenterologists, about the latest clinical trial results could increase prescriptions, especially for pregnant patients.

Key Takeaways

  1. PROCTOFOAM HC has demonstrated efficacy and safety in treating hemorrhoids during pregnancy, filling a crucial gap in obstetric care.

  2. Recent supply chain challenges have been overcome, with the product returning to the Canadian market.

  3. The aging population and increasing awareness of anorectal health present growth opportunities for PROCTOFOAM HC.

  4. Ongoing innovation, including potential formulation improvements and expanded clinical studies, will be crucial for maintaining market position.

  5. Geographic expansion and targeted outreach to healthcare providers could drive future growth.

FAQs

  1. Q: Is PROCTOFOAM HC safe to use during pregnancy? A: Yes, recent clinical trials have shown that PROCTOFOAM HC is safe and effective for use during the third trimester of pregnancy.

  2. Q: How does PROCTOFOAM HC differ from other hemorrhoid treatments? A: PROCTOFOAM HC combines hydrocortisone acetate for anti-inflammatory effects with pramoxine hydrochloride for local anesthetic properties in a unique foam formulation.

  3. Q: Are there any ongoing supply issues with PROCTOFOAM HC? A: While there was a shortage in 2022, the manufacturer has worked to resolve these issues. However, it's always best to check with your local pharmacy for current availability.

  4. Q: Can PROCTOFOAM HC be used for conditions other than hemorrhoids? A: Yes, PROCTOFOAM HC is approved for use in various anorectal conditions including proctitis, cryptitis, anal fissures, and postoperative pain.

  5. Q: What are the future prospects for PROCTOFOAM HC in the market? A: With its proven efficacy, especially in pregnancy, and the growing aging population, PROCTOFOAM HC is well-positioned for future growth. However, it may face challenges from generic competition and will need to continue innovating to maintain its market position.

Sources cited: [1] https://pubmed.ncbi.nlm.nih.gov/19761640/ [2] https://www.drugshortagescanada.ca/shortage/158393 [3] https://www.newswire.ca/news-releases/proctofoam-hc-r-back-in-canadian-pharmacies-868821834.html [4] https://pubmed.ncbi.nlm.nih.gov/21352635/ [5] https://www.rxlist.com/proctofoam-hc-drug.htm [7] https://mentalhealth.networkofcare.org/Lake/CommunityResources/ClinicalTrials/Detail/NCT00405288 [8] https://pdf.hres.ca/dpd_pm/00031398.PDF

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.